Statement by the Board of Directors of Recipharm regarding the public offer from Roar BidCo
The Board of Directors unanimously recommends the shareholders and holders of convertible bonds to accept the offer from Roar BidCo. This statement is made by the board of directors of Recipharm AB (publ) (“Recipharm”) pursuant to Rule II.19 of the Nasdaq Stockholm Takeover Rules (the ”Takeover Rules”). The Offer On 14 December 2020, EQT IX, through Roar BidCo AB (the “Offeror”), announced a public offer of SEK 220 per share to the shareholders of Recipharm after having submitted an indicative offer to the board of SEK 196 per share at an initial stage. Today, 28 January 2021, the